Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of New Biomarkers to Improve Diagnostics or Predict Treatment Responses, Adverse Events or Prognosis in Patients With Inflammatory Rheumatic Disease Followed in the Danish Nationwide Quality Registry, DANBIO

NCT03214263 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT03214263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03214263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of New Biomarkers to Improve Diagnostics or Predict Treatment Responses, Adverse Events or Prognosis in Patients With Inflammatory Rheumatic Disease Followed in the Danish Nationwide Quality Registry, DANBIO
Lead sponsor
Rigshospitalet, Denmark
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2024
Enrollment
20,000 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, axial spondyloarthritis, connective tissue diseases, gout, psoriatic arthritis